Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/8/2026

Intradialytic Hypertension: Assessment, Management, and Associated Anxiety

Immediate Cardiovascular Assessment

  • Obtain a 12‑lead ECG promptly to rule out myocardial ischemia or arrhythmias in patients who develop palpitations during dialysis. (KDOQI guideline, American Journal of Kidney Diseases, 2005) 1
  • Measure cardiac troponin when palpitations accompany a hypertensive episode, because dialysis patients often present with atypical cardiac symptoms. (KDOQI guideline, American Journal of Kidney Diseases, 2005) 1

Volume‑Related Dialysis Modifications

  • Temporarily reduce or pause ultrafiltration if the patient appears volume‑depleted; rapid fluid removal can trigger paradoxical hypertension via sympathetic activation. (KDOQI guideline, American Journal of Kidney Diseases, 2005) 1
  • Reassess the target dry weight over the ensuing 4–12 weeks, as chronic volume overload is a frequent driver of dialysis‑associated hypertension. (KDOQI guideline, American Journal of Kidney Diseases, 2005) 1
  • Avoid aggressive ultrafiltration rates; keep UF ≤ 6 mL/h/kg to maintain hemodynamic stability. (Praxis Medical Insights, 2026) 2
  • Keep the prescribed ultrafiltration rate below 6 mL/h/kg; higher rates are linked to intradialytic hypotension and symptomatic instability. (Praxis Medical Insights, 2026) 2

Blood‑Pressure Thresholds and Pharmacologic Considerations

  • A blood pressure of 180/90 mmHg does not meet criteria for a hypertensive emergency; cardiovascular events in dialysis patients rise markedly only when systolic pressure approaches ≈180 mmHg. (KDOQI guideline, American Journal of Kidney Diseases, 2005) 1
  • Clonidine is substantially dialyzable and its plasma concentration does not change markedly during hemodialysis; therefore, acute sublingual dosing is not an effective strategy for intradialytic hypertension. (KDOQI guideline, American Journal of Kidney Diseases, 2005) 1
  • Adding an antihypertensive agent during active ultrafiltration can precipitate dangerous intradialytic hypotension in this high‑risk population. (Praxis Medical Insights, 2026) 2

Anxiety and Palpitations

  • Approximately 45 % of dialysis patients experience anxiety, which frequently manifests as palpitations, tremor, and dyspnea. (KDOQI guideline, American Journal of Kidney Diseases, 2005) 3
  • Cognitive‑behavioral therapy or mindfulness‑based interventions have been shown to reduce anxiety symptoms in hemodialysis patients. (Kidney International, 2023) 4
  • Music therapy administered during dialysis sessions can lower anxiety levels and improve pain perception. (Kidney International, 2023) 4
  • Selective serotonin reuptake inhibitors should be used cautiously in dialysis patients because of heightened gastrointestinal adverse effects and limited evidence of benefit over placebo. (Kidney International, 2023) 4
  • Benzodiazepines are not recommended for routine intradialytic anxiety; they should be reserved for severe, refractory cases under specialist supervision. (Praxis Medical Insights, 2026) 2

Long‑Term Blood‑Pressure Management

Dialysis Prescription Optimization

  • Extend each dialysis session to a minimum of 4 hours and slow ultrafiltration rates to improve hemodynamic stability. (Praxis Medical Insights, 2026) 2
  • Lower dialysate temperature to 34–35 °C; this reduces symptomatic complications from 44 % to 34 %. (Praxis Medical Insights, 2026) 2
  • Implement early‑session sodium profiling with dialysate sodium ≈148 mEq/L to mitigate intradialytic symptoms. (Praxis Medical Insights, 2026) 2

Dietary and Volume Control

  • Restrict dietary sodium to <5.8 g/day (ideally 2–3 g/day) to lessen thirst and interdialytic weight gain. (Praxis Medical Insights, 2026) 2
  • Limit interdialytic weight gain to <3 % of body weight between sessions. (Praxis Medical Insights, 2026) 5
  • Achieve euvolemia through gradual dry‑weight reduction over 4–12 weeks with regular dietitian follow‑up. (KDOQI guideline, American Journal of Kidney Diseases, 2005) 1

Pharmacologic Antihypertensive Therapy

  • Add calcium‑channel blockers and β‑blockers as second‑ and third‑line agents when predialysis BP remains >140/90 mmHg after dry‑weight optimization. (KDOQI guideline, American Journal of Kidney Diseases, 2005) 1
  • Reserve minoxidil for resistant hypertension that is uncontrolled on a three‑drug regimen. (KDOQI guideline, American Journal of Kidney Diseases, 2005) 1

Prognostic Blood‑Pressure Ranges

  • Both markedly high (>180 mmHg systolic) and markedly low (<110 mmHg systolic or <70 mmHg diastolic) predialysis blood pressures are associated with increased mortality in dialysis patients. (KDOQI guideline, American Journal of Kidney Diseases, 2005) 1

Critical Pitfalls to Avoid

  • Do not administer antihypertensive medications during active ultrafiltration without first evaluating volume status and cardiac function. (Praxis Medical Insights, 2026) 2
  • Do not dismiss palpitations as “only anxiety”; cardiac disease accounts for ~50 % of dialysis‑related deaths, mandating thorough cardiovascular assessment. (Praxis Medical Insights, 2026) 2
  • Do not give indiscriminate saline boluses for blood‑pressure control, as this worsens volume overload. (Praxis Medical Insights, 2026) 2
  • Do not continue a twice‑weekly dialysis schedule in patients with recurrent intradialytic symptoms, because it forces dangerously high ultrafiltration rates. (Praxis Medical Insights, 2026) 5

Monitoring and Follow‑Up

  • Screen all dialysis patients regularly for depression and anxiety using validated instruments; these conditions affect roughly 25–50 % of the population. (Kidney International, 2023; KDOQI guideline, American Journal of Kidney Diseases, 2005) [4][3]

Management of Intradialytic Hypertension and Associated Symptoms

Pharmacologic Considerations for Intradialytic Hypertension

  • Clonidine is not removed by hemodialysis and its plasma level remains essentially unchanged during treatment; therefore, a single sublingual dose is ineffective for controlling intradialytic hypertension. (American Society of Nephrology) 6
  • A predialysis systolic blood pressure of 180 mmHg does not meet criteria for a hypertensive emergency; cardiovascular events rise sharply only when systolic pressure reaches ≥180 mmHg, and both markedly high (>180 mmHg) and markedly low (<110 mmHg systolic or <70 mmHg diastolic) predialysis pressures are linked to higher mortality. (American Society of Nephrology) 6

Volume Management as the Primary Driver of Hypertension

  • Chronic volume overload is the leading cause of hypertension in hemodialysis patients; reassessing and adjusting the target dry weight over the next 4–12 weeks is recommended to improve blood‑pressure control. (Kidney Disease: Improving Global Outcomes) 7

Antihypertensive Medication Selection After Volume Optimization

  • When predialysis blood pressure remains >140/90 mmHg after dry‑weight optimization, calcium‑channel blockers (e.g., amlodipine) and β‑blockers (e.g., carvedilol, labetalol) are advised as second‑ and third‑line agents. (Kidney Disease: Improving Global Outcomes) 7
  • Non‑dialyzable β‑blockers such as carvedilol and labetalol are preferred over highly dialyzable agents (e.g., atenolol, metoprolol) to maintain intradialytic protection against arrhythmias. (Kidney Disease: Improving Global Outcomes) 7
  • ACE inhibitors or ARBs (e.g., benazepril, fosinopril) are recommended because they reduce left‑ventricular hypertrophy and are associated with lower mortality in this population. (Kidney Disease: Improving Global Outcomes) 7
  • If a persistent cough is attributed to an ACE inhibitor, switching to an ARB is suggested, acknowledging the residual risk of angioedema with ARBs. (American Heart Association) 8

Evaluation and Management of Cough in Hemodialysis Patients

  • ACE‑inhibitor–induced cough occurs in approximately 5–10 % of patients and typically presents as a non‑productive, persistent throat tickle. (American Heart Association) 8
  • Gastro‑esophageal reflux disease (GERD) is a major contributor to cough in dialysis patients, with an overall cough prevalence of about 22 % in this group. (American Thoracic Society) 9
  • Pulmonary edema secondary to volume overload is also a common cause of cough in hemodialysis patients. (American Thoracic Society) 9

REFERENCES

2

Immediate Management of Severe Hypoxemia in Hemodialysis Patients [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

5

Sudden Ear Fullness with Hearing Loss and Tinnitus during Hemodialysis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026